A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine combined with chemotherapy after surgery to remove pancreatic cancer.
Researchers are combining TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, to see if they work on pancreatic and other gastrointestinal cancers.
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.